Please assess the completion status of the following clinical trial:

Trial Title: Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures.~2. Understands and agrees to comply with planned study procedures.~3. Male or non-pregnant female adult ≥18 years of age at time of enrollment.~4. Subject consents to randomization within 72 hours of hospital admission or transfer from another facility within 72 hours of index presentation.~5. Subjects with a positive COVID-19 diagnosis by nasal swab or serologic testing.~6. Hospitalized with a requirement for supplemental oxygen.~7. Have:~   * Either a D- Dimer \> 4.0 X ULN, OR~  * Sepsis-induced coagulopathy (SIC) score of ≥4~Exclusion Criteria:~1. Indications for therapeutic anticoagulation~2. Absolute contraindication to anticoagulation including:~   1. active bleeding,~  2. recent (within 1 month) history of bleed,~  3. dual (but not single) antiplatelet therapy,~  4. active gastrointestinal and intracranial cancer,~  5. a history of bronchiectasis or pulmonary cavitation,~  6. Hepatic failure with a baseline INR \> 1.5,~  7. CrCl \< 15ml/min,~  8. a platelet count \< 25,000,~  9. a history of heparin-induced thrombocytopenia (HIT) within the past 100 days or in the presence of circulating antibodies,~  10. contraindications to enoxaparin including a hypersensitivity to enoxaparin sodium, hypersensitivity to heparin or pork products, hypersensitivity to benzyl alcohol,~  11. pregnant female,~  12. inability to give or designate to give informed consent,~  13. participation in another blinded trial of investigational drug therapy for COVID-19

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Full Dose LMWH anticoagulation therapy (Type: EXPERIMENTAL): Subjects in this study arm will be treated with therapeutic doses of subcutaneous low-molecular-weight heparin (enoxaparin). Enoxaparin 1mg/kg SQ BID for CrCl ≥ 30ml/min (or Enoxaparin 0.5mg/kg SQ BID for CrCl ≥ 15ml/min and \< 30ml/min) during the course of their hospitalization.
- Prophylactic/Intermediate Dose LMWH or UFH therapy (Type: ACTIVE_COMPARATOR): Subjects in this study arm will be treated with Local institutional standard-of-care for prophylactic-dose or intermediate-dose UFH or LMWH. Regimens allowed are UFH up to 22,500 IU daily in BID or TID doses (i.e. UFH 5000 IU SQ BID/TID or 7500 IU BID/TID), enoxaparin 30mg and 40mg SQ QD or BID (the use of weight-based enoxaparin i.e. 0.5mg/kg SQ BID for this arm is acceptable but strongly discouraged), dalteparin 2500IU or 5000IU QD.

Based on this trial design, predict the completion outcome and termination type (if applicable).